Clinical trial
5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer
NCT00189657 · Association Européenne de Recherche en Oncologie, Other · Unknown status
Key facts
| NCT number | NCT00189657 |
|---|---|
| Title | 5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer |
| Lead sponsor | Association Européenne de Recherche en Oncologie, Other |
| Collaborators | Aventis Pharmaceuticals Industry Pfizer |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer of the Rectum |
| Intervention type | Procedure |
| Interventions | 5FU/LV Mayo Clinic or LV5FU2, LV5FU2 + irinotecan |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 19, 2005 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: